potent pan-PIM kinase inhibitor

oral PD and efficacy in xenograft model

from SBDD of prior lead

Bioorg. Med. Chem. Lett., Oct. 14, 2020

Sanofi, Waltham/Cambridge, MA

“compound 27” (Sanofi oral in vivo pan-PIM kinase inhibitor)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks